Liquidia Corporation - Common Stock (LQDA)

Liquidia (LQDA) Q1 2026 Earnings Transcript

Liquidia (NASDAQ:LQDA) reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. On the company’s earnings call, Chi

This biotech firm develops therapies for rare pulmonary diseases, leveraging proprietary drug delivery technology in the U.S. market.

Biotech innovator Liquidia, specializing in pulmonary therapies, reported a notable insider sale amid continued growth in its core market.

This biotech focused on pulmonary therapies reported a notable insider sale amid strong share price gains and rising revenue.

Biotech innovator Liquidia, focused on therapies for rare conditions, reported a notable insider sale amid strong recent share performance.

This biotech innovator in rare disease therapies reported significant insider selling amid a year of robust stock performance.

Dave Inc. delivers digital banking and personal finance tools designed to offer alternatives to traditional banking platforms.

Liquidia (LQDA) Q4 2025 Earnings Call Transcript

Product revenue from YUTREPIA reached approximately $148.3 million in 2025, including about $90.1 million generated during the fourth quarter alone.

Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.

Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.

United Therapeutics Corporation (Nasdaq: UTHR) has long been a favorite of biotech investors who value both steady cash flows and visionary "moonshot" projects. On February 25, 2026, the company cemented its status as a high-performance healthcare powerhouse by reporting a significant Q4 2025 earnings beat and officially surpassing the $3 billion annual revenue milestone for [...]

As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary arterial hypertension (PAH), the company has recently captured Wall Street’s attention with a series of high-stakes maneuvers. Following a stellar Q4 2025 earnings report released [...]

The company is clearly benefiting from the solid momentum of its newest drug on the market.

Liquidia Corp (LQDA) exemplifies a high-growth momentum stock in a strong technical uptrend, combining surging revenue with a top-rated chart pattern.

One fund just walked away from a rising offshore driller—here’s what long-term investors should make of the move.

A fast-growing niche segment may be the real reason this small-cap consumer products stock is drawing new institutional attention.